Perspectives in Clinical Proteomics Conference: Translating clinical proteomics into clinical practice

Expert Review of Proteomics

Volumn 7, Issue 4, 2010, Pages 469-471

  Sturgeon, Catharine ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

biomarker discovery; clinical proteomics; translational research

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DEMENTIA; HUMAN; MEDICAL RESEARCH; MEDICAL SOCIETY; MULTICENTER STUDY; PATIENT CARE; PROTEOMICS;

BIOLOGICAL MARKERS; HUMANS; PROTEOMICS;

EID: 77954971780     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.10.74     Document Type: Conference Paper

References (5)

1. Rodriguez H, Snyder M, Uhlen M et al. Recommendations from the 2008 International Summit on Proteomics Data Release and Sharing Policy: the Amsterdam principles. J. Proteome Res. 8(7), 3689-3692 (2009).
2. Hemingway H, Riley RD, Altman DG. Ten steps towards improving prognosis research. BMJ 339, 410-414 (2009).
3. Sturgeon CM, Hoffman BR, Chan DW et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin. Chem. 54(8), e1-e10 (2008).
4. Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J. Clin. Oncol. 28(4), 698-704 (2010).
5. Banks RE, Patterson S. Perspectives in proteomics. Proteomics Clin. Appl. (2010) (In Press).